The p53 Pathway in Malignant Primary CNS Tumors: From Molecular Biology to Therapeutic Opportunities

The p53 signaling pathway is a key regulator of genomic stability and cellular stress responses. Beyond TP53 mutations, p53 dysfunction in malignant primary central nervous system (CNS) tumors results from multiple genetic and epigenetic alterations, contributing to tumor initiation, progression, therapeutic resistance, and interactions with the tumor microenvironment. Recent advances have transformed p53 from a classical tumor suppressor into an attractive therapeutic target. This review summarizes the current understanding of the molecular biology of the p53 pathway in malignant primary CNS tumors and discusses emerging therapeutic strategies aimed at restoring or exploiting p53 signaling. Current evidence from experimental, translational, and clinical studies was critically reviewed, with particular emphasis on IDH-wildtype glioblastoma, IDH-mutant astrocytoma, pediatric-type diffuse high-grade gliomas, medulloblastoma, and other malignant CNS tumors. The molecular mechanisms of p53 pathway dysregulation and recent advances in p53-targeted therapies were analyzed. Accumulating evidence demonstrates that p53 pathway dysregulation extends beyond TP53 mutations and involves aberrant MDM2/MDM4 activity, altered stress-response signaling, mutant p53 gain-of-function, and epigenetic mechanisms. Therapeutic approaches targeting these alterations—including MDM2/MDM4 inhibitors, mutant p53 reactivators, direct p53-targeting compounds, gene- and RNA-based therapies, and rational combination strategies—have shown encouraging preclinical and early clinical activity. However, tumor heterogeneity, blood–brain barrier penetration, adaptive resistance, and the need for biomarker-guided patient selection remain major obstacles to successful clinical translation. The p53 pathway represents a potential therapeutic target in neuro-oncology, although the clinical efficacy of p53-directed approaches in primary CNS tumors remains unestablished. Further studies are required to determine whether molecularly guided strategies can translate into meaningful clinical benefit.

Authors

Institutions

Publication Details

Journal
Brain Sciences
Published
2026-11-19
DOI
https://doi.org/10.3390/brainsci16111268
Primary Topic
Cancer-related Molecular Pathways
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The p53 Pathway in Malignant Primary CNS Tumors: From Molecular Biology to Therapeutic Opportunities

Mai Ly Thi Nguyen, Khắc Cường Bùi, Przemyslaw M. Bozko, Phuong Linh Thi Nham et al.
Brain Sciences
Cancer-related Molecular Pathways
article

The p53 Pathway in Malignant Primary CNS Tumors: From Molecular Biology to Therapeutic Opportunities

Mai Ly Thi Nguyen, Khắc Cường Bùi, Przemyslaw M. Bozko, Phuong Linh Thi Nham, Maria Bożko, Tai Suc Nguyen, Anh Tho Thi Tran, Dennis Rangno, Viet Hao Tran, Linh Toan Nguyen
article en

Abstract

The p53 signaling pathway is a key regulator of genomic stability and cellular stress responses. Beyond TP53 mutations, p53 dysfunction in malignant primary central nervous system (CNS) tumors results from multiple genetic and epigenetic alterations, contributing to tumor initiation, progression, therapeutic resistance, and interactions with the tumor microenvironment. Recent advances have transformed p53 from a classical tumor suppressor into an attractive therapeutic target. This review summarizes the current understanding of the molecular biology of the p53 pathway in malignant primary CNS tumors and discusses emerging therapeutic strategies aimed at restoring or exploiting p53 signaling. Current evidence from experimental, translational, and clinical studies was critically reviewed, with particular emphasis on IDH-wildtype glioblastoma, IDH-mutant astrocytoma, pediatric-type diffuse high-grade gliomas, medulloblastoma, and other malignant CNS tumors. The molecular mechanisms of p53 pathway dysregulation and recent advances in p53-targeted therapies were analyzed. Accumulating evidence demonstrates that p53 pathway dysregulation extends beyond TP53 mutations and involves aberrant MDM2/MDM4 activity, altered stress-response signaling, mutant p53 gain-of-function, and epigenetic mechanisms. Therapeutic approaches targeting these alterations—including MDM2/MDM4 inhibitors, mutant p53 reactivators, direct p53-targeting compounds, gene- and RNA-based therapies, and rational combination strategies—have shown encouraging preclinical and early clinical activity. However, tumor heterogeneity, blood–brain barrier penetration, adaptive resistance, and the need for biomarker-guided patient selection remain major obstacles to successful clinical translation. The p53 pathway represents a potential therapeutic target in neuro-oncology, although the clinical efficacy of p53-directed approaches in primary CNS tumors remains unestablished. Further studies are required to determine whether molecularly guided strategies can translate into meaningful clinical benefit.

Brain SciencesVol. 16(11)
Vinh Medical University (VN), Universitätsklinikum Tübingen (DE), Vinmec Times City International Hospital (VN), Vietnam Military Medical University (VN), Hanoi University of Pharmacy (VN), VinUniversity (VN), Vietnamese - German Center of Excellence in Medical Research (VN), 108 Military Central Hospital (VN), University of Warsaw (PL), University of Tübingen (DE)
Cancer-related Molecular Pathways
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon